These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 38848180)

  • 1. Plasma pTau181 Predicts Clinical Progression in a Phase 2 Randomized Controlled Trial of the 11β-HSD1 Inhibitor Xanamem® for Mild Alzheimer's Disease.
    Taylor J; Jaros M; Chen C; Harrison J; Hilt D
    J Alzheimers Dis; 2024; 100(1):139-150. PubMed ID: 38848180
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-Aβ protofibril antibody.
    Swanson CJ; Zhang Y; Dhadda S; Wang J; Kaplow J; Lai RYK; Lannfelt L; Bradley H; Rabe M; Koyama A; Reyderman L; Berry DA; Berry S; Gordon R; Kramer LD; Cummings JL
    Alzheimers Res Ther; 2021 Apr; 13(1):80. PubMed ID: 33865446
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Brain 11β-Hydroxysteroid Dehydrogenase Type 1 Occupancy by Xanamem™ Assessed by PET in Alzheimer's Disease and Cognitively Normal Individuals.
    Villemagne VL; Doré V; Chong L; Kassiou M; Mulligan R; Feizpour A; Taylor J; Roesner M; Miller T; Rowe CC
    J Alzheimers Dis; 2024; 97(3):1463-1475. PubMed ID: 38250767
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial.
    Wilcock GK; Black SE; Hendrix SB; Zavitz KH; Swabb EA; Laughlin MA;
    Lancet Neurol; 2008 Jun; 7(6):483-93. PubMed ID: 18450517
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Amyloid positron emission tomography and cerebrospinal fluid results from a crenezumab anti-amyloid-beta antibody double-blind, placebo-controlled, randomized phase II study in mild-to-moderate Alzheimer's disease (BLAZE).
    Salloway S; Honigberg LA; Cho W; Ward M; Friesenhahn M; Brunstein F; Quartino A; Clayton D; Mortensen D; Bittner T; Ho C; Rabe C; Schauer SP; Wildsmith KR; Fuji RN; Suliman S; Reiman EM; Chen K; Paul R
    Alzheimers Res Ther; 2018 Sep; 10(1):96. PubMed ID: 30231896
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PTI-125 Reduces Biomarkers of Alzheimer's Disease in Patients.
    Wang HY; Pei Z; Lee KC; Lopez-Brignoni E; Nikolov B; Crowley CA; Marsman MR; Barbier R; Friedmann N; Burns LH
    J Prev Alzheimers Dis; 2020; 7(4):256-264. PubMed ID: 32920628
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of the efficacy, safety and tolerability of orally administered BI 409306, a novel phosphodiesterase type 9 inhibitor, in two randomised controlled phase II studies in patients with prodromal and mild Alzheimer's disease.
    Frölich L; Wunderlich G; Thamer C; Roehrle M; Garcia M; Dubois B
    Alzheimers Res Ther; 2019 Feb; 11(1):18. PubMed ID: 30755255
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase 2A Learnings Incorporated into RewinD-LB, a Phase 2B Clinical Trial of Neflamapimod in Dementia with Lewy Bodies.
    Prins ND; de Haan W; Gardner A; Blackburn K; Chu HM; Galvin JE; Alam JJ
    J Prev Alzheimers Dis; 2024; 11(3):549-557. PubMed ID: 38706271
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial.
    Lannfelt L; Blennow K; Zetterberg H; Batsman S; Ames D; Harrison J; Masters CL; Targum S; Bush AI; Murdoch R; Wilson J; Ritchie CW;
    Lancet Neurol; 2008 Sep; 7(9):779-86. PubMed ID: 18672400
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase II study repurposing atomoxetine for neuroprotection in mild cognitive impairment.
    Levey AI; Qiu D; Zhao L; Hu WT; Duong DM; Higginbotham L; Dammer EB; Seyfried NT; Wingo TS; Hales CM; Gámez Tansey M; Goldstein DS; Abrol A; Calhoun VD; Goldstein FC; Hajjar I; Fagan AM; Galasko D; Edland SD; Hanfelt J; Lah JJ; Weinshenker D
    Brain; 2022 Jun; 145(6):1924-1938. PubMed ID: 34919634
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer's disease and frontotemporal lobar degeneration: a retrospective diagnostic performance study.
    Thijssen EH; La Joie R; Strom A; Fonseca C; Iaccarino L; Wolf A; Spina S; Allen IE; Cobigo Y; Heuer H; VandeVrede L; Proctor NK; Lago AL; Baker S; Sivasankaran R; Kieloch A; Kinhikar A; Yu L; Valentin MA; Jeromin A; Zetterberg H; Hansson O; Mattsson-Carlgren N; Graham D; Blennow K; Kramer JH; Grinberg LT; Seeley WW; Rosen H; Boeve BF; Miller BL; Teunissen CE; Rabinovici GD; Rojas JC; Dage JL; Boxer AL;
    Lancet Neurol; 2021 Sep; 20(9):739-752. PubMed ID: 34418401
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparing tau status determined via plasma pTau181, pTau231 and [
    Tissot C; Therriault J; Kunach P; L Benedet A; Pascoal TA; Ashton NJ; Karikari TK; Servaes S; Lussier FZ; Chamoun M; Tudorascu DL; Stevenson J; Rahmouni N; Poltronetti NM; Pallen V; Bezgin G; Kang MS; Mathotaarachchi SS; Wang YT; Fernandez Arias J; Ferreira PCL; Ferrari-Souza JP; Vanmechelen E; Blennow K; Zetterberg H; Gauthier S; Rosa-Neto P
    EBioMedicine; 2022 Feb; 76():103837. PubMed ID: 35134647
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase 2 double-blind placebo-controlled 24-week treatment clinical study of the p38 alpha kinase inhibitor neflamapimod in mild Alzheimer's disease.
    Prins ND; Harrison JE; Chu HM; Blackburn K; Alam JJ; Scheltens P;
    Alzheimers Res Ther; 2021 May; 13(1):106. PubMed ID: 34044875
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of the Correlation and Diagnostic Accuracy between Cerebrospinal Fluid and Plasma Alzheimer's Disease Biomarkers: A Comparison of the Lumipulse and Simoa Platforms.
    Dakterzada F; Cipriani R; López-Ortega R; Arias A; Riba-Llena I; Ruiz-Julián M; Huerto R; Tahan N; Matute C; Capetillo-Zarate E; Piñol-Ripoll G
    Int J Mol Sci; 2024 Apr; 25(9):. PubMed ID: 38731812
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma p-tau231: a new biomarker for incipient Alzheimer's disease pathology.
    Ashton NJ; Pascoal TA; Karikari TK; Benedet AL; Lantero-Rodriguez J; Brinkmalm G; Snellman A; Schöll M; Troakes C; Hye A; Gauthier S; Vanmechelen E; Zetterberg H; Rosa-Neto P; Blennow K
    Acta Neuropathol; 2021 May; 141(5):709-724. PubMed ID: 33585983
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phosphorylated tau-Aβ42 ratio as a continuous trait for biomarker discovery for early-stage Alzheimer's disease in multiplex immunoassay panels of cerebrospinal fluid.
    Harari O; Cruchaga C; Kauwe JS; Ainscough BJ; Bales K; Pickering EH; Bertelsen S; Fagan AM; Holtzman DM; Morris JC; Goate AM;
    Biol Psychiatry; 2014 May; 75(9):723-31. PubMed ID: 24548642
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Research diagnostic criteria for Alzheimer's disease: findings from the LipiDiDiet randomized controlled trial.
    Rosenberg A; Solomon A; Soininen H; Visser PJ; Blennow K; Hartmann T; Kivipelto M;
    Alzheimers Res Ther; 2021 Mar; 13(1):64. PubMed ID: 33766132
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selection and early clinical evaluation of the brain-penetrant 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitor UE2343 (Xanamem™).
    Webster SP; McBride A; Binnie M; Sooy K; Seckl JR; Andrew R; Pallin TD; Hunt HJ; Perrior TR; Ruffles VS; Ketelbey JW; Boyd A; Walker BR
    Br J Pharmacol; 2017 Mar; 174(5):396-408. PubMed ID: 28012176
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnostic value of plasma phosphorylated tau181 in Alzheimer's disease and frontotemporal lobar degeneration.
    Thijssen EH; La Joie R; Wolf A; Strom A; Wang P; Iaccarino L; Bourakova V; Cobigo Y; Heuer H; Spina S; VandeVrede L; Chai X; Proctor NK; Airey DC; Shcherbinin S; Duggan Evans C; Sims JR; Zetterberg H; Blennow K; Karydas AM; Teunissen CE; Kramer JH; Grinberg LT; Seeley WW; Rosen H; Boeve BF; Miller BL; Rabinovici GD; Dage JL; Rojas JC; Boxer AL;
    Nat Med; 2020 Mar; 26(3):387-397. PubMed ID: 32123386
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Head-to-Head Comparison Between Plasma pTau181 and Tau PET Along the Alzheimer's Disease Continuum.
    Coomans EM; Verberk IMW; Ossenkoppele R; Verfaillie SCJ; Visser D; Gouda M; Tuncel H; Wolters EE; Timmers T; Windhorst AD; Golla SSV; Scheltens P; van WM; Flier D; van Berckel BNM; Teunissen CE
    J Nucl Med; 2023 Mar; 64(3):437-443. PubMed ID: 36229187
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.